CRVS
$4.05
Corvus Pharma Com
CRVS
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.25)
Revenue:  $0.00 Mil
Tuesday
Oct 27
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CRVS reports earnings?
Beat
Meet
Miss

Where is CRVS's stock price going from here?
Up
Flat
Down
Stock chart of CRVS
Analysts
Summary of analysts' recommendations for CRVS
Score
Grade
Pivots
Resistance
$4.21
$4.17
$4.11

$4.07

Support
$4.01
$3.97
$3.91
Tweet
Growth
Description
Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. Corvus Pharmaceuticals, Inc. is based in Burlingame, California.